Body fat composition determines outcomes before and after liver transplantation in patients with cirrhosis

Cornelius Engelmann, Niklas F. Aehling, Stefan Schob, Ines Nonnenmacher, Luise Handmann, Jane Macnaughtan, Adam Herber, Alexey Surov, Thorsten Kaiser, Timm Denecke, Rajiv Jalan, Daniel Seehofer, Michael Moche, Thomas Berg – 13 April 2022 – Cachexia occurs in late stages of liver cirrhosis, and a low‐fat mass is potentially associated with poor outcome. This study compared different computed tomography (CT)–derived fat parameters with respect to its prognostic impact on the development of complications and death before and after liver transplantation.

Effect of hepatic steatosis and associated metabolic comorbidities on health‐related quality of life in people living with HIV

Maurice Michel, Christian Labenz, Malena Anders, Alisha Wahl, Lisann Girolstein, Leonard Kaps, Wolfgang M. Kremer, Yvonne Huber, Peter R. Galle, Martin Sprinzl, Jörn M. Schattenberg – 11 April 2022 – Hepatic steatosis (HS) related to nonalcoholic fatty liver disease (NAFLD) is increasing globally. In people living with human immunodeficiency virus (PLWH) risk factors of HS are increased. The impact of HS on outcomes and in particular health‐related quality of life (HRQL) in PLWH remains unknown.

Palliative care experience and perceived gaps in training among transplant hepatology fellows: A national survey

Maureen P. Whitsett, Nneka N. Ufere, Arpan Patel, Judy A. Shea, Christopher A. Jones, Oren K. Fix, Marina Serper – 10 April 2022 – Despite the likely benefits of palliative care (PC) for patients with cirrhosis, physician experiences and perspectives about best practices are variable. We aimed to assess PC experience and gaps in training among transplant hepatology fellows. We conducted a national survey of all transplant hepatology fellows enrolled in accredited fellowship programs during the 2020–2021 academic year.

Variants in mitochondrial amidoxime reducing component 1 and hydroxysteroid 17‐beta dehydrogenase 13 reduce severity of nonalcoholic fatty liver disease in children and suppress fibrotic pathways through distinct mechanisms

Christian A. Hudert, Leon A. Adams, Anna Alisi, Quentin M. Anstee, Annalisa Crudele, Laura G. Draijer, EU‐PNAFLD investigators, Samuel Furse, Jan G. Hengstler, Benjamin Jenkins, Kylie Karnebeek, Deirdre A. Kelly, Bart G. Koot, Albert Koulman, David Meierhofer, Phillip E. Melton, Trevor A. Mori, Stuart G. Snowden, Indra Mourik, Anita Vreugdenhil, Susanna Wiegand, Jake P.

Subscribe to